---
title: "禮來計劃擴大與普渡大學的協議，計劃在 8 年內投資 2.5 億美元。"
description: "禮來計劃擴大與普渡大學的協議，計劃在 8 年內投資 2.5 億美元。"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/239564370.md"
published_at: "2025-05-09T12:04:25.000Z"
---

# 禮來計劃擴大與普渡大學的協議，計劃在 8 年內投資 2.5 億美元。

禮來計劃擴大與普渡大學的協議，計劃在 8 年內投資 2.5 億美元。

### Related Stocks

- [LLY.US - 禮來](https://longbridge.com/zh-HK/quote/LLY.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Eli Lilly and Company $LLY Shares Acquired by Assetmark Inc. | Assetmark Inc. increased its holdings in Eli Lilly and Company (NYSE: LLY) by 6.0% in Q3, owning 55,360 shares valued at | [Link](https://longbridge.com/zh-HK/news/275971336.md) |
| Eli Lilly: Mirikizumab approved in China for treatment of moderate-to-severe Crohn's disease and ulcerative colitis - Co statement | Eli Lilly: Mirikizumab approved in China for treatment of moderate-to-severe Crohn's disease and ulcerative colitis - Co | [Link](https://longbridge.com/zh-HK/news/275551012.md) |
| Eli Lilly (LLY) Builds $1.5 Billion Inventory of Weight-Loss Pill | Eli Lilly (LLY) has prepared a $1.5 billion inventory of its new weight-loss pill, Orforglipron, ahead of its anticipate | [Link](https://longbridge.com/zh-HK/news/276070062.md) |
| Novo Nordisk plans to launch Wegovy vials | Novo Nordisk plans to launch Wegovy in vials, exploring various device presentations, with some launching this year. Cur | [Link](https://longbridge.com/zh-HK/news/275661935.md) |
| Lilly's bowel disease drug gets approval in China  | Eli Lilly has received approval from Chinese regulators for its drug mirikizumab, aimed at treating chronic inflammatory | [Link](https://longbridge.com/zh-HK/news/275554667.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。